Lupin launches onychomycosis topical solution in US market

The product will be manufactured at Lupin’s facility in Pithampur

Lupin announced the US launch of Tavaborole Topical Solution, 5 per cent having received approval from the United States Food and Drug Administration (FDA). The product will be manufactured at Lupin’s facility in Pithampur.

Tavaborole Topical Solution, 5 per cent, is the generic equivalent of Kerydin Topical Solution, 5 per cent, of Anacor Pharmaceuticals, and is an oxaborole antifungal indicated for the topical treatment of onychomycosis of the toenails due to Trichophyton rubrum or Trichophyton mentagrophytes. Tavaborole Topical Solution (RLD: Kerydin), 5 per cent has an estimated annual sales of $53 million in the US.